Literature DB >> 12377638

Is cisplatin still the best platinum compound in non-small-cell lung cancer?

J-C Soria, T Le Chevalier.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377638     DOI: 10.1093/annonc/mdf331

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis.

Authors:  Tetsuya Isaka; Hiroyuki Ito; Haruhiko Nakayama; Tomoyuki Yokose; Kayoko Katayama; Kouzo Yamada; Munetaka Masuda
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

2.  Platinum-Based Adjuvant Chemotherapy for Stage II and Stage III Squamous Cell Carcinoma of the Lung.

Authors:  Tetsuya Isaka; Haruhiko Nakayama; Tomoyuki Yokose; Hiroyuki Ito; Kayoko Katayama; Kouzo Yamada; Munetaka Masuda
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-12-27       Impact factor: 1.520

3.  Inhibition of DNA Synthesis by a Platinum-Acridine Hybrid Agent Leads to Potent Cell Kill in Non-Small Cell Lung Cancer.

Authors:  Christopher L Smyre; Gilda Saluta; Timothy E Kute; Gregory L Kucera; Ulrich Bierbach
Journal:  ACS Med Chem Lett       Date:  2011-08-31       Impact factor: 4.345

4.  Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.

Authors:  Jie Luo; Shiang J Leaw; Ying Xu; Di Zheng
Journal:  Med Oncol       Date:  2010-07-27       Impact factor: 3.064

5.  A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer.

Authors:  Zhidong Ma; Jayati Roy Choudhury; Marcus W Wright; Cynthia S Day; Gilda Saluta; Gregory L Kucera; Ulrich Bierbach
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.